News

A test by Veracyte can be used to predict which patients with interstitial lung diseases (ILDs), including idiopathic pulmonary fibrosis (IPF), are more likely to experience progressive decline in their lung function, according to new data. Called the Envisia Genomic Classifier, the test works by identifying the genomic…

The cellular aging of a group of cells called alveolar type 2 pneumocytes — which work to promote airway stability, and play a key role in lung repair after injury — may be responsible for driving pulmonary fibrosis (PF). That’s according to new findings from a team led by…

The first patient has been enrolled in a Phase 3 clinical trial of Tyvaso (treprostinil) inhalation solution for patients with idiopathic pulmonary fibrosis (IPF), according to the therapy’s developer, United Therapeutics. Called TETON 2 (NCT05255991), the trial will evaluate the treatment’s efficacy against a placebo in about…

BenevolentAI has identified a new treatment target for idiopathic pulmonary fibrosis (IPF) that will be added to AstraZeneca’s therapeutic discovery portfolio. This is the third IPF target identified by the platform for the biopharmaceutical company following previous discoveries. Another AI-generated target for chronic kidney disease (CKD)…

The treatment candidate RXC007 demonstrated promising efficacy in easing fibrosis, or scarring, in mouse models of idiopathic pulmonary fibrosis (IPF) and other scarring-related conditions. In healthy human volunteers participating in a recently-completed Phase 1 trial, RXC007 displayed a good safety and pharmacological profile. Now, Redx Pharma, the company…

Dosing has begun in healthy volunteers in a Phase 1 clinical trial evaluating the safety and pharmacological properties of LASN01, an experimental therapy for pulmonary fibrosis and other diseases characterized by excessive tissue scarring, or fibrosis. “The initiation of this trial is an important milestone for Lassen and continues…

Bellerophon Therapeutics has gotten the green light to cut by about half the number of patients who may enter REBUILD, its ongoing Phase 3 trial of INOpulse (inhaled nitric oxide) for the treatment of pulmonary hypertension linked to pulmonary fibrosis. The downsizing may help the company complete the…

Piceatannol, a natural compound with antioxidant and anti-inflammatory properties, eased the signs and symptoms of pulmonary fibrosis (PF) in mice, a study reported. According to its researchers, these findings indicate that piceatannol could be a promising treatment candidate for PF. The study, “Piceatannol-mediated JAK2/STAT3 signaling pathway inhibition…

Algernon Pharmaceuticals has filed for orphan drug status for NP-120 (ifenprodil), an experimental oral medicine for patients with idiopathic pulmonary fibrosis (IPF) who have persistent, hard-to-treat cough. “The FDA has a standard response time of 90 days to requests for orphan designation, and so we should know by…

Treatment with Haduvio (nalbuphine extended-release tablets) significantly reduced coughing for people with idiopathic pulmonary fibrosis (IPF), according to top-line data from the Phase 2 CANAL trial. “It is very promising to see such a significant reduction in chronic cough in IPF patients with [Haduvio],” Peter Dicpinigaitis, MD, a professor…